Glial Nrf2 signaling mediates the neuroprotection exerted by *Gastrodia elata* Blume in Lrrk2-G2019S Parkinson's disease

Yu-En Lin^{1,2}, Chin-Hsien Lin³, En-Peng Ho³, Yi-Ci Ke³, Stavroula Petridi^{4,5}, Christopher J. H. Elliott⁴,
Lee-Yan Sheen^{2,*}, and Cheng-Ting Chien^{1,6,*}

¹Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan

²Institute of Food Science and Technology, National Taiwan University, Taipei, Taiwan

³Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan

⁴Department of Biology and York Biomedical Research Institute, University of York, York, UK

⁵Department of Clinical Neurosciences and MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK

⁶Neuroscience Program of Academia Sinica, Academia Sinica, Taipei, Taiwan

*Correspondence:

Lee-Yan Sheen, E-mail: lysheen@ntu.edu.tw, Tel.: +886-2-3366-1572

Cheng-Ting Chien, E-mail: ctchien@gate.sinica.edu.tw, Tel.: +886-2-2789-9970

Abstract

The most frequent missense mutations in familial Parkinson's disease (PD) occur in the highly conserved *LRRK2/PARK8* gene with G2019S mutation. We previously established a fly model of PD carrying the *LRRK2-G2019S* mutation that exhibited the parkinsonism-like phenotypes. An herbal medicine—*Gastrodia elata* Blume (GE), has been reported to have neuroprotective effects in toxin-induced PD models. However, the underpinning molecular mechanisms of GE beneficiary to G2019S-induced PD remain unclear. Here, we show that these G2019S flies treated with water extracts of GE (WGE) and its bioactive compounds, gastrodin and 4-HBA, displayed locomotion improvement and dopaminergic neuron protection. WGE suppressed the accumulation and hyperactivation of G2019S proteins in dopaminergic neurons, and activated the antioxidation and detoxification factor Nrf2 mostly in the astrocyte-like and ensheathing glia. Glial activation of Nrf2 antagonizes G2019S-induced Mad/Smad signaling. Moreover, we treated *LRRK2-G2019S* transgenic mice with WGE and found the locomotion declines, the loss of dopaminergic neurons, and the number of hyperactive microglia were restored. WGE also suppressed the hyperactivation of G2019S proteins and regulated the Smad2/3 pathways in the mice brains. We conclude that WGE prevents locomotion defects and the neuronal loss induced by G2019S mutation via glial Nrf2/Mad signaling, unveiling a potential therapeutic avenue for PD.

Introduction

Parkinson's disease (PD) is a highly prevalent neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra projecting to the striatum of the basal ganglion, representing a circuit involved in motor planning and coordination. As a consequence, PD is associated with motor abnormalities, bradykinesia, hypokinesia, rigidity and resting tremor. Currently, the most frequently applied pharmacological treatment, levodopa (L-DOPA), exerts limited motor improvement and elicits negative side-effects (Ray Chaudhuri et al., 2018). Hence, identifying and developing alternative or complementary treatments may assist in mitigating PD progression.

PD is a multi-causal disease with a complicated etiology, including familial inheritance. More than 20 *PARK* genes have been genetically linked to PD, a number that is increasing (Houlden & Singleton, 2012). Missense mutations in *PARK8*, or *Leucine-rich repeat kinase 2* (*LRRK2*) induce characteristic PD symptoms and pathologies such as loss of dopaminergic neurons and the appearance of Lewy bodies (Martin et al., 2014). Notably, the most commonly observed mutation, dominant G2019S, among familial PD cases is located in the kinase domain of *Lrrk2*, which augments its kinase activity via auto- and hyper-activation (Sheng et al., 2012). The hyperactive G2019S mutant protein alters several cellular processes, including vesicle trafficking, microtubule dynamics, autophagy, mitochondrial function (Martin et al., 2014), and most commonly, increases susceptibility to oxidative stress that contributes to neuronal degeneration (Angeles et al., 2011; Nguyen et al., 2011). These indicate that regulation of the hyperactivation of G2019S mutant protein appears to be a disease-modifying strategy.

Glia provide structural and metabolic supports to neurons and regulate synaptic transmissions, so they are important for the function and survival of dopaminergic neurons (Lin et al., 1993; Sofroniew & Vinters, 2010). Dysfunction in two major glial types, astrocytes and microglia, contribute to the onset and progression of both sporadic and familial PD (Kam et al., 2020). Astrocytes and microglia of postmortem PD brains exhibit pathologic lesions and hyper-immunoactivity (Miklossy et al., 2006). A clinical trial involving down-regulation of microglial oxidative stress highlights the significance of glia to PD (Jucaite et al., 2015). Moreover, *Lrrk2* regulates the inflammatory response in microglia and the autophagy-

lysosome pathway in astrocytes, with the G2019S mutation altering the size and pH of lysosomes (Henry et al., 2015; Moehle et al., 2012). Expression of G2019S mutant protein in neurons was previously shown to induce the secretion of Glass bottom boat (Gbb)/bone morphogenetic protein (BMP) signal that, in turn, upregulates Mothers against decapentaplegic (Mad)/Smad signaling in glia, which prompts feedback signals to promote neuronal degeneration (Maksoud et al., 2019). These studies indicate that G2019S mutant protein alters the homeostasis and interaction between neurons and glia, contributing to PD pathogenesis. However, whether any dietary or pharmacological treatment blockading this neuron-glia interaction beneficiary to G2019S-induced PD is unclear.

Given that up to 70% of human *PARK* genes are conserved in the *Drosophila* genome, *Drosophila* is frequently used as a PD model for studying gene function, such as the *PARK1/SNCA* (Chen & Feany, 2005) and *PARK8/LRRK2* (Liu et al., 2008). Genetic and molecular linkage between *PINK1/PARK6* and *Parkin/PARK2* was first established in *Drosophila* (Clark et al., 2006). When overexpressed in *Drosophila* dopaminergic neurons, *LRRK2* transgenes carrying G2019S or other dominant mutations induce dopaminergic neuron loss and locomotion impairment, two age-dependent symptoms of PD (Lin et al., 2010; Liu et al., 2008). The G2019S model has further been used to screen a collection of FDA-approved drugs to suppress these PD phenotypes. Thus, *Drosophila* represents an amenable model of PD for genetic, molecular and pharmacological study of potential therapeutic interventions. Strikingly, lovastatin was found to prevent dendrite degeneration, dopaminergic neuron loss, and impaired locomotion and, critically, a lovastatin-involved Nrf2 pathway proved neuroprotective (C. H. Lin et al., 2016). Nevertheless, whether the Nrf2-mediated neuroprotection is cell- or non-cell-autonomous, remaining elusive.

Traditional Chinese Medicine (TCM) is often used as an alternative or dietary treatment for human diseases, including PD (Kim et al., 2012; Li et al., 2017). Although the results were inconclusive, some TCM could display adjuvant effects when used in combination with L-DOPA, reducing the L-DOPA dosage required in long-term treatments and relieving non-motor symptoms (Kim et al., 2012). As a prominent component in TCM, *Gastrodia elata* Blume (GE; Orchidaceae) has been used to treat

neurological disorders for centuries (Chen & Sheen, 2011). GE has been shown to exert neuroprotective, anti-inflammatory and antioxidative effects in neurodegenerative disease models (Jang et al., 2015). The major bioactive compounds in GE include gastrodin and 4-hydroxybenzyl alcohol (4-HBA), both of which display pharmacological effects on neurobiological and psychological disorders (Chen et al., 2016; Kumar et al., 2013). Additionally, gastrodin and 4-HBA have been reported to activate the Nrf2 signaling in dopaminergic neurons and astrocytes, respectively (Jiang et al., 2014; Luo et al., 2017), highlighting a potential benefit of incorporating GE in PD treatments. However, the effects and mechanisms underlying how GE moderate Lrrk2-G2019S PD remain unclear.

In the present study, we treated G2019S animals with water extract of GE (WGE), and its bioactive compounds, gastrodin and 4-HBA. We have investigated the impact of WGE treatment on PD in restoring locomotion and protecting dopaminergic neurons in the *Drosophila* G2019S model. We identified two distinct pathways induced by WGE in the model, i.e., suppression of Lrrk2 protein accumulation and hyperphosphorylation in neurons, and activation of the Nrf2 pathway in glia, particularly in astrocyte-like and ensheathing glia. We show that WGE-induced Nrf2 activation antagonizes the Gbb-activated Mad signaling in glia, contributing to neuronal protection. WGE also suppressed the hyperactivation of G2019S proteins and antagonized Smad2/3 signaling in a *LRRK2-G2019S* mouse model, which restored locomotion, protected dopaminergic neurons and regulated the microglia hyperactivation. Conservation of the pathways impacted by WGE treatment in both the *Drosophila* and mouse G2019S models implies that the beneficial effects of GE and represent a reliable and effective complementary therapy for PD.

Results

WGE treatment improves locomotion of *Ddc>G2019S* flies

We employed the *GAL4-UAS* system to express the human G2019S mutant of Lrrk2 by the *Ddc-GAL4* driver (*Ddc>G2019S*) in dopaminergic neurons and then assessed the anti-geotactic climbing activity of adult flies. We observed that locomotion of *Ddc>G2019S* flies was affected significantly relative to control flies expressing human wild-type Lrrk2 (*Ddc>Lrrk2*) (Figure 1A and Figure 1-figure supplement 1A). At weeks 1 and 2, more than 80% of *Ddc>G2019S* flies could successfully climb above an 8-cm threshold, a proportion comparable to that of *Ddc>Lrrk2* flies. However, the success rate declined to ~40% at week 3, ~20% at week 4, and to less than 10% at weeks 5 and 6. These proportions are significantly lower than the ~80% at week 3, ~60% at week 4, and ~40% at weeks 5 and 6 displayed by *Ddc>Lrrk2* flies. Although both *Ddc>G2019S* and *Ddc>Lrrk2* flies failed to reach the 8-cm mark at weeks 7 and 8, *Ddc>Lrrk2* flies could still climb the wall, whereas almost all *Ddc>G2019S* flies could not (Figure 1-figure supplement 1A). We also tested the climbing activity of another control expressing GFP in dopaminergic neurons (*Ddc>mCD8-GFP*). Both *Ddc>Lrrk2* and *Ddc>mCD8-GFP* flies showed comparable climbing activities in the first six weeks, and a significant number of *Ddc>mCD8-GFP* flies were still able to climb above the 8-cm mark at week 7. Therefore, we used the *Ddc>Lrrk2* line as a control for *Ddc>G2019S* flies in subsequent experiments to dissect the specific mode of pathogenicity of the G2019S mutation.

Next, we examined the effect of feeding flies with water extracts of GE (WGE) as a dietary supplement at different concentrations (0.1, 0.5 or 1.0%, w/w). WGE treatment of *Ddc>G2019S* flies at all three doses elicited a significant improvement in their climbing ability (Figure 1A). Strikingly, the lowest concentration (0.1%) of WGE proved the most effective, with *Ddc>G2019S* flies still performing well at climbing (i.e., comparably to *Ddc>Lrrk2* control flies) in weeks 5 and 6. The higher doses of WGE (0.5 % and 1.0%) still exerted beneficial effects at weeks 3 and 4, albeit not as significantly as the 0.1% dose, but had no beneficial effect in weeks 5 and 6. As 0.1% is the lowest among the three doses tested, we lowered the dose of WGE to 0.02% and found that 0.02% WGE was less effective than 0.1%

starting at week 3 till week 6, suggesting that 0.1% is the optimal dose in restoring the climbing activity of *Ddc>G2019S* flies (Figure 1-figure supplement 1B).

Gastrodin and 4-HBA are two major phenolic compounds in GE displaying neuropharmacological effects (Zhan et al., 2016). Feeding *Ddc>G2019S* flies with food containing gastrodin (0.1 mM) equivalent to the amount in 0.1% WGE also restored locomotion of *Ddc>G2019S* flies in weeks 2-4, though its impact diminished to non-significant levels at weeks 5 and 6. However, increasing the gastrodin dose ten-fold (1.0 mM) resulted in improved climbing activity at weeks 5 and 6 (Figure 1B). Similarly, the equivalent 0.1 mM of 4-HBA, the aglyconic form of gastrodin and the bioactive form in the brain (Wu et al., 2017), was sufficient to restore the climbing ability of *Ddc>G2019S* flies, and a ten-fold dose at 1.0 mM had an even better effect (Figure 1C). These results indicate that both gastrodin and 4-HBA are primary bioactive compounds in GE that prevent locomotion decline in *Ddc>G2019S* flies, and higher doses are more beneficial to reach the effect as WGE did.

Success in the anti-gravity wall-climbing assay also requires an immediate response to startle knockdown. Accordingly, we performed a second assay, free-walking in an open arena, to assess improved locomotion. Consistently, free-walking by *Ddc>G2019S* flies was greatly impaired, with total walking distance reduced to less than 20% that displayed by control *Ddc>Lrrk2* flies (Figure 1D). Moreover, *Ddc>G2019S* flies displayed centrophobism, i.e., they avoided walking into the central open space. Strikingly, 0.1% WGE feeding greatly extended walking distance and suppressed the centrophobism of *Ddc>G2019S* flies. Together, these two assays strongly indicate that the defective locomotion exhibited by *Ddc>G2019S* flies is greatly improved by feeding them with 0.1% WGE. Because the improvement on the locomotion was more effective in flies fed with 0.1% WGE than the pure compounds, we therefore fed the flies with 0.1% WGE in the following experiments.

WGE treatment suppresses dopaminergic neuron loss in *Ddc>G2019S* brain

Expression of G2019S mutant protein has been shown to induce a gradual loss of dopaminergic neurons in the adult fly brain, contributing to impaired locomotion (Lin et al., 2010; Liu et al., 2008).

Several clusters of dopaminergic neurons have been identified in the adult brain of *Drosophila*. Here, we focused on the PPL1, PPL2, PPM1/2 and PPM3 clusters that have well-defined roles in modulating locomotion (Mao & Davis, 2009) to assess the effect of WGE treatment. We detected reduced numbers of dopaminergic neurons in the PPL1, PPL2, PPM1/2, and PPM3 clusters of *Ddc>G2019S* flies relative to *Ddc>Lrrk2* controls, which increased in severity from week 2 to 6 (Figure 2 and Figure 2-figure supplement 1A to C). Consistently, feeding *Ddc>G2019S* flies with 0.1% WGE restored numbers of dopaminergic neurons in these clusters to the levels observed in controls (Figure 2 and Figure 2-figure supplement 1A to C). Thus, concomitant rescue of locomotion and dopaminergic neuron populations in *Ddc>G2019S* flies indicates that WGE treatment likely promotes dopaminergic neuron survival to restore locomotion.

WGE treatment suppresses G2019S-induced Lrrk2 hyperactivation

The enhanced survival of dopaminergic neurons due to WGE treatment implies that WGE induces neuroprotective mechanisms in *Ddc>G2019S* flies. The G2019S mutation causes Lrrk2 hyperphosphorylation, protein accumulation, and aberrant cellular signaling (Price et al., 2018). Therefore, we explored if WGE-induced neuroprotection is responsible for abrogating these processes in G2019S flies. We detected comparable levels of Lrrk2 proteins in newly eclosed adult brains pan-neuronally expressing wild-type Lrrk2 (*elav>Lrrk2*) or G2019S mutant protein (*elav>G2019S*) (Figure 3A). However, phosphorylation levels at the Ser¹²⁹² autophosphorylation site was higher in the *elav>G2019S* flies compared to *elav>Lrrk2* (Figure 3A and B). This outcome was also observed at week 4 (Figure 3F and G), consistent with the idea that Lrrk2 is hyperactivated upon G2019S mutation. Hyperphosphorylation in *elav>G2019S* flies led to Lrrk2 protein accumulation, as determined by total Lrrk2 levels at weeks 2 and 4 (Figure 3D and E). However, both hyperphosphorylation and protein accumulation were suppressed upon feeding *elav>G2019S* flies with 0.1% WGE (Figure 3D to G). In the *elav>Lrrk2* control, WGE feeding had no effect on levels of wild-type Lrrk2 or Ser¹²⁹² phosphorylation (Figure 3-figure supplement 1A to C). We further examined the G2019S mutant-activated downstream

effector Rab10, the phosphorylation status of which can serve as an indicator of Lrrk2 kinase activity (Karayel et al., 2020). We observed that levels of phosphorylated Rab10 were increased in *elav>G2019S* flies, but this phenotype was suppressed by WGE feeding (Figure 3F and H). Hence, feeding flies with WGE suppresses G2019S-induced Lrrk2 protein phosphorylation, accumulation, and signaling.

WGE treatment restores Akt/GSK3 β /Nrf2 pathway activity

The Akt/GSK3 β /Nrf2 signaling axis has been shown to promote survival of dopaminergic neurons and ameliorate motor dysfunction in PD models (C. H. Lin et al., 2016). We assayed the phosphorylation status of Akt at Ser⁵⁰⁵ in newly eclosed adult fly head extracts and found reduced levels of pAkt in *elav>G2019S* flies relative to *elav>Lrrk2* controls (Figure 3A and C). This pAkt reduction persisted at weeks 2 and 4, but was abrogated by feeding *elav>G2019S* flies with 0.1% WGE (Figure 4A and B). We also examined phosphorylation levels of Nrf2 at Ser⁴⁰ and GSK3 β at Ser⁹, both of which were reduced upon expression of G2019S mutant protein and were equally offset by WGE feeding (Figure 4C and D). Induction of Akt/GSK3 β /Nrf2 signaling activates expression of heme oxygenase 1 (HO-1), and we observed diminished levels of this latter protein in *elav>G2019S* flies, which could be rescued by WGE feeding (Figure 4C and D). Therefore, WGE feeding restores the Akt/GSK3 β /Nrf2 signaling activity compromised by the G2019S mutation.

Glial Nrf2 mediates the beneficial effect of WGE on restored locomotion and neuronal protection in G2019S flies

Restoration of Akt/GSK3 β /Nrf2 signaling activity by WGE treatment prompted us to test by genetic assays if that signaling pathway mediates the WGE mode of action. We focused on the downstream effector Nrf2 encoded by *cap-n-collar (cnc)* in *Drosophila*. Intriguingly, neither overexpression (*UAS-cnc-FL2*) nor RNAi knockdown (*UAS-cncTRiP*) of Nrf2 in dopaminergic neurons had an impact on the climbing ability of *Ddc>G2019S* flies (Figure 5A). Also, WGE feeding still rescued locomotion of *Ddc>G2019S* flies with Nrf2 knockdown (*Ddc>G2019S; cncTRiP*) to levels comparable to WGE-fed

control flies (*Ddc>G2019S; mCD8-GFP*) without Nrf2 knockdown (Figure 5A). Thus, the Nrf2 pathway activation by WGE that appears to be effective in protecting neurons and restoring locomotion is likely exerted in cells other than neurons.

Nrf2 activation may be examined by assessing GFP signal from the *ARE-GFP* reporter that harbors Nrf2 binding sites and responds to Nrf2 activation (Chatterjee & Bohmann, 2012). *ARE-GFP* adult fly brains displayed low basal GFP signals (Figure 5C), but feeding with 0.1% WGE elicited many GFP-positive signals in Repo-positive glia (arrowheads in Figure 5D), evidencing that glia may be the primary cell type in which Nrf2 is activated.

Next, we investigated if WGE-induced Nrf2 activity in glia is effective in promoting locomotion in *G2019S* flies. To this end, we employed the *LexA-LexAop* system to overexpress wild-type *Lrrk2* or *G2019S* mutant protein in dopaminergic neurons (*Ddc-LexA>Lrrk2* and *Ddc-LexA>G2019S*, respectively), and used the *GAL4* driver to manipulate Nrf2/CncC activity in glia (*repo>cncC-FL2* for overexpression and *repo>cncC-RNAi* for knockdown). As a first step, we validated the age-dependent locomotion decline of *Ddc-LexA>G2019S* flies that was severer than *Ddc-LexA>Lrrk2* and could be rescued by 0.1% WGE feeding (Figure 5-figure supplement 1). We then assayed the climbing ability of *Ddc-LexA>G2019S* flies exhibiting *repo-GAL4*-driven Nrf2 overexpression in glia (*Ddc-LexA>G2019S; repo>cncC-FL2*). Significantly, the *Ddc-LexA>G2019S; repo>cncC-FL2* flies performed better in the climbing assay than *Ddc-LexA>G2019S; repo-GAL4* without Nrf2 overexpression (Figure 5B). We also performed Nrf2 knockdown in glia (*Ddc-LexA>G2019S; repo>cncC-RNAi*), which had little impact on the already declined climbing activity in *Ddc-LexA>G2019S; repo-GAL4* (Figure 5B). Importantly, WGE feeding could not rescue locomotion deficits of glial Nrf2-knockdown flies (*Ddc-LexA>G2019S; repo>cncC-RNAi*) (Figure 5B, compare to *Ddc-LexA>G2019S; repo-GAL4* with WGE feeding). Thus, glial overexpression of Nrf2 partially restores locomotion of *Ddc-LexA>G2019S* flies, and glial depletion of Nrf2 abolishes the ability of WGE to rescue impaired locomotion.

We stained dopaminergic neurons of 6-week-old adult fly brains and confirmed that numbers of TH-positive dopaminergic neurons in the PPL1 cluster were reduced in the *Ddc-LexA>G2019S; repo-GAL4*

flies compared to *Ddc-LexA>Lrrk2; repo-GAL4* controls (Figure 5E and F). Importantly, numbers of dopaminergic neurons in the PPL1 cluster were restored upon glial overexpression of Nrf2 in the *Ddc-LexA>G2019S; repo>cncC-FL2* flies. In contrast, glial Nrf2 knockdown had little impact on the already reduced dopaminergic neurons. Taken together, these results support that glial Nrf2 is compromised in *Ddc-LexA>G2019S* flies, and glial expression of Nrf2 protects the dopaminergic neurons.

Although WGE feeding suppressed hyperactivity of G2019S mutant protein (Figure 3D to G), it was not clear if WGE-mediated Nrf2 activation in glia could directly suppress mutant protein hyperactivity in dopaminergic neurons. To test this possibility, we compared the levels of total Lrrk2 protein and phosphorylated Lrrk2 protein in *Ddc-LexA>G2019S* with and without glial Nrf2 overexpression (*Ddc-LexA>G2019S; repo-GAL4* and *Ddc-LexA>G2019S; repo>cncC*). We observed comparable levels of Lrrk2 and pLrrk2 in the control and Nrf2 overexpression lines (Figure 6-figure supplement 1A to C). Thus, the neuroprotective effects of Nrf2 activity are unlikely to operate through modulation of Lrrk2 levels or activity.

Nrf2 in astrocyte-like and ensheathing glia are the major targets of WGE that alleviate *Lrrk2-G2019S* locomotion deficits

Five types of glia with different morphologies and functions have been identified in the fly brain (Freeman, 2015). We decided to identify specific subtypes of glia that may mediate the WGE-induced Nrf2 activity endowing neuronal protection, given that dysfunctional astrocytes and microglia have been linked to onset and progression of both sporadic and familial PD (Kam et al., 2020). In *Ddc-LexA>G2019S* flies, *GAL4*-driven *cnc* knockdown in astrocyte-like (*Ddc-LexA>G2019S; alrm>cnc-RNAi*) or ensheathing glia (*Ddc-LexA>G2019S; R56F03>cnc-RNAi*) abolished the improved locomotion elicited by WGE treatment, recapitulating the effect of pan-glial Nrf2 knockdown (*Ddc-LexA>G2019S; repo>cnc-RNAi*) (Figure 6A). This outcome was not observed when we used *GAL4* drivers to knock down *cnc* in cortex (*np2222*), perineurial (*np6293*), or subperineurial (*moody*) glia. We confirmed the involvement of astrocyte-like and ensheathing glia by means of Nrf2 overexpression in astrocyte-like

(*Ddc-LexA>G2019S*; *alrm>cncC-FL2*) or ensheathing (*Ddc-LexA>G2019S*; *R56F03>cncC-FL2*) glia, with both treatments improving the climbing activity of *Ddc-LexA>G2019S* flies not subjected to WGE feeding (Figure 6B). These analyses indicate that WGE feeding induces Nrf2 activity in astrocyte-like and ensheathing glia, which mitigates the reduced locomotion displayed by G2019S mutant-expressing flies.

Next, we assayed Nrf2-regulated *ARE-GFP* expression in astrocyte-like and ensheathing glia of flies expressing G2019S mutant protein and subjected to WGE treatment. We focused on the astrocyte-like and ensheathing cells located adjacent to dopaminergic neurons. In control flies expressing wild-type *Lrrk2*, we detected basal levels of GFP signal in mCherry-positive astrocyte-like (*alrm-GAL4*) or ensheathing glia (*R56F03*) (Figure 6C to F). We detected lower levels of GFP signal in these cells when G2019S mutant protein was expressed in dopaminergic neurons. However, upon feeding with 0.1% WGE, we observed higher levels of GFP signal in both types of glia. Thus, overexpression of G2019S mutant protein in dopaminergic neurons elicited reduced Nrf2 signaling activity, but WGE feeding restored or further enhanced Nrf2 activities in these two glial subtypes.

Nrf2 activation antagonizes BMP signaling in glia

G2019S mutant protein in dopaminergic neurons has been shown previously to enhance the expression of the proprotein convertase Furin 1 (*Fur1*) that processes the bone morphogenetic protein (BMP) signaling molecule Glass bottom boat (*Gbb*) for maturation and release, leading to activation of the BMP signaling pathway in glia (Maksoud et al., 2019). We confirmed that finding by removing one copy of *Mad* that encodes the pathway's downstream effector to restore locomotion in *Ddc>G2019S* flies (Figure 7-figure supplement 1). To address if WGE-induced Nrf2 activation could antagonize BMP signaling activity in glia, first we assessed expression of the phosphorylated Mad (pMad) activated by BMP signaling. In glia of *Ddc>G2019S* adult fly brains, pMad levels were higher than in *Ddc>Lrrk2* brains and they could be suppressed by WGE treatment (Figure 7A and B). Similar to the previous report (Maksoud et al., 2019), glial overexpression of Mad (*UAS-Mad*) or constitutively active type I receptor

Tkv (*UAS-tkv^{Q253D}*) was sufficient to impair locomotion, even without expressing G2019S mutant protein in neurons. However, impaired locomotion was rescued in both cases by 0.1% WGE feeding (Figure 7C and D). In addition, numbers of dopaminergic neurons in the PPL1 cluster were reduced upon glial overexpression of *Mad* or *tkv^{Q253D}* and they were restored by 0.1% WGE treatment (Figure 7E to H). Together, these analyses indicate that activation of BMP signaling in glia recapitulates the phenotypes observed in flies overexpressing G2019S mutant protein in dopaminergic neurons and, furthermore, that these effects can be suppressed by WGE treatment.

Next, we explored if WGE-induced Nrf2 activation antagonizes BMP signaling in glia. Glial Nrf2 overexpression in *Ddc-LexA>G2019S* flies (*Ddc-LexA>G2019S; repo>cncC-FL2*) partially rescued the locomotory impairment caused by G2019S mutation (Figure 5B), and removing one copy of *Mad* (*Ddc-LexA>G2019S, Mad^{+/-}; repo>cncC-FL2*) further enhanced this effect (Figure 8A). Indeed, this outcome was equivalent to removing one copy of *Mad* but without Nrf2 overexpression (*Ddc-LexA>G2019S, Mad^{+/-}; repo-GAL4*), suggesting that Nrf2 functions mainly to antagonize Mad activity (Figure 8A). Consistently, Nrf2 overexpression in glia or WGE treatment suppressed the up-regulation of pMad levels in glia caused by G2019S mutant protein overexpression in dopaminergic neurons (*Ddc-LexA>G2019S; repo-GAL4*) (Figure 8B and C). Depletion of Nrf2 from glia (*Ddc-LexA>G2019S; repo>cnc-RNAi*), even in the presence of WGE treatment, maintained high pMad levels in glia (Figure 8B and C). Thus, modulation of Nrf2 activity, either by genetic manipulation or by WGE treatment, has an antagonistic effect on pMad levels in glia.

We also addressed if *Mad* modulates expression of the Nrf2 target *ARE-GFP*. We observed diminished GFP signal in PPL1-surrounding glia of *Ddc-LexA>G2019S* adult fly brains relative to the *Ddc-LexA>Lrrk2* control. Heterozygosity of *Mad* in *Ddc-LexA>G2019S* flies (*Ddc-LexA>G2019S, Mad^{+/-}*) restored the level of GFP signal, implying that *Mad* modulates targeted gene expression induced by Nrf2 activity (Figure 8D and E).

The effects of WGE treatment in a *LRRK2-G2019S* mouse model

To further study the effect of WGE on G2019S mutation-induced neurodegeneration in a mammalian system, we fed *LRRK2-G2019S* transgenic mice with WGE starting at the age of 8.5 months, i.e., prior to onset of impairments in locomotion and dopaminergic neurons (Chou et al., 2014). We quantified three locomotor activities from video-tracking paths of an open-field test, i.e., accumulative moving distance, average velocity, and percentage of time moving (Figure 9A and B). At the age of 8.5 months, three groups—non-transgenic (nTg), transgenic *LRRK2-G2019S*, and WGE-fed transgenic *LRRK2-G2019S* mice—presented comparable locomotor activities. At 9.5 months of age, the *LRRK2-G2019S* mice displayed clearly impaired locomotion, which was statistically significant at the age of 11.5 months relative to nTg littermates (Figure 9B), consistent with a previous report (Chen et al., 2012). Importantly, the *LRRK2-G2019S* mice fed with WGE showed improved locomotion throughout the 3-month treatment period, an outcome that was statistically significant at 11.5 months (Figure 9 A and B). WGE treatment also suppressed the centrophobism displayed by *LRRK2-G2019S* mice (Figure 9A). We also analyzed the gait of these three groups of mice (Figure 9C). Similar to our findings from the open field test, stride length of *LRRK2-G2019S* mice was significantly reduced at 11.5 months, but it was restored to the level of nTg mice by WGE feeding (Figure 9C and D). Collectively, these analyses show that WGE feeding is an effective means of restoring G2019S mutation-induced locomotory declines in this mouse model of PD.

Since the nigral-striatal system contributes to locomotor function, we counted the number of TH-positive dopaminergic neurons in the substantia nigra. In comparison to nTg littermates, the number of dopaminergic neurons in 11.5-month-old *LRRK2-G2019S* mice was significantly reduced, but WGE treatment for three months abrogated this loss of dopaminergic neurons (Figure 10A and B). In the *Ddc>G2019S Drosophila* model, glia mediate the protective effects of WGE on dopaminergic neurons. We found that activated microglia marked by ionized calcium-binding adapter molecule 1 (Iba-1) were increased in the substantia nigra of *LRRK2-G2019S* mice, but this increase was suppressed by WGE treatment (Figure 10C and D). We further analyzed levels of activated LRRK2 (pLRRK2) in lysates isolated from the nigra-striatum. Levels of pLRRK2 normalized to LRRK2 signal were higher in *LRRK2-*

G2019S mice than in nTg littermates, but WGE treatment partially abrogated that outcome (Figure 10E and F). Since *G2019S* mutation enhanced Mad signaling activation in the fly brain (Figure 8B and C), we also tested this scenario in the mouse model. Immunoblots revealed that the ratio of phosphorylated Smad2 to total Smad2 (pSmad2/Smad2) was significantly elevated in *LRRK2-G2019S* mice, but this increase was suppressed by WGE treatment (Figure 10E and G). Moreover, although the level of pSmad3/Smad3 was not significantly enhanced by *G2019S* mutant protein expression, it was suppressed by WGE treatment (Figure 10E and G). Thus, WGE feeding suppresses *G2019S* mutation-induced microglia activation and Smad signaling in the substantia nigra of the *LRRK2-G2019S* mouse model of PD.

In summary, the potential mechanisms of WGE involved in the modulation of the neuron-glia interaction are proposed (Figure 11). WGE regulates the hyperactivation of *G2019S* mutant protein in dopaminergic neurons, and antagonizes the Mad signaling by activating the Nrf2 pathway in glia. Both actions provide neuroprotection.

Discussion

Motor dysfunction in *Drosophila* neurodegeneration models has been frequently evaluated by means of negative-geotaxis assay that measures the insect innate response. The assay begins with a sudden external stimulation, which initially inhibits spontaneous locomotion but is followed by climbing behavior. The entire response requires motor circuit coordination and muscle tone regulation, two processes that progressively decline with age and that are impacted by neuropathological insults (Grotewiel et al., 2005). In contrast, the open-arena walking assay allows free exploration without disturbance, representing an assay for locomotor activities that can reveal deficits like bradykinesia (Chen et al., 2014). Our G2019S flies exhibited reduced locomotor activity in both assays. Moreover, the G2019S flies also exhibited centrophobism-like behavior in the open-arena (Figure 1D). Centrophobism is indicative of emotional abnormalities, such as anxiety and depression, both of which are often associated with PD (Kulisevsky et al., 2008), and was also displayed by the *LRRK2-G2019S* mice (Figure 9A). WGE treatment suppresses centrophobism in both fly and mouse PD models has important implications for tackling major symptoms of PD and even non-PD-related depression, as reported for rodent models (Lin et al., 2018; Y. E. Lin et al., 2016). Thus, WGE treatment exerts beneficial effects in both of our PD models.

We found that the 0.1% dosage of WGE is optimal in suppressing age-dependent locomotion decline in G2019S flies, with higher and lower doses being less effective (Figure 1A and Figure 1-figure supplement 1B). Although an inverted U-shaped drug response is common, a plausible explanation for the diminished effectiveness of higher doses is that WGE downregulates the day-time but not night-time locomotor activity of flies (Jo et al., 2017). In mice, higher WGE doses have sleep-promoting effects by activating adenosine A₁/A_{2A} receptors in the ventrolateral preoptic area (Zhang et al., 2012). Thus, dosage level is critical to the beneficial effects of GE in both PD models.

Gastrodin and 4-HBA are considered the principal active components in GE (Zhan et al., 2016). Although both compounds can cross the blood-brain barrier (Wu et al., 2017), the capability of gastrodin to do so is relatively poor compared to aglyconic 4-HBA due to the glucose moiety (Lin et al., 2007).

Gastrodin is quickly metabolized to 4-HBA and undetermined metabolites in the brain (Lin et al., 2008), perhaps explaining the lower effectiveness of gastrodin in G2019S flies. However, it is likely that the combination of gastrodin with other components in GE might exert optimal beneficial effects.

Expression of G2019S mutant protein impacts different clusters of dopaminergic neurons in the fly brain that are known for their connectivity and function. Activation of two specific mushroom body (MB)-projection dopaminergic neurons in the PPL1 cluster inhibits climbing performance (Sun et al., 2018). Mutations in the circadian gene *Clock* (*Clk*) cause PPL1 dopaminergic neuron degeneration, accelerating impaired age-associated climbing ability (Vaccaro et al., 2017). Dopaminergic neurons in the PPL2 cluster extend processes to the calyx of the MB, which has been linked to climbing activity (Sun et al., 2018). In contrast, PPM3 neurons project to the central complex, activation of which enhances locomotion (Kong et al., 2010). A significant reduction in dopaminergic neurons in the PPM1/2 cluster was only found at week 4 when impaired locomotion of G2019S flies was prominent. In a PD fly model involving *SNCA* overexpression and *aux* knockdown, dopaminergic neurons in the PPM1/2 cluster were selectively degenerated and this phenotype was accompanied by impaired locomotion in relatively young adult flies (Song et al., 2017). We postulate that the age-dependent impaired locomotion displayed by G2019S flies could be caused by gradual and differential loss of dopaminergic neurons in these clusters, thereby affecting different aspects of locomotion. However, further study is needed to test that hypothesis.

Expression of the G2019S mutant protein induces Lrrk2 auto- and hyper-phosphorylation, as well as protein accumulation, together enhancing cellular Lrrk2 activity and causing aberrant downstream signaling (Sheng et al., 2012). We have shown here that neuronal expression of Lrrk2-G2019S reduced Akt phosphorylation (Figure 4A and B). Consistently, hyperactivated G2019S mutant protein impaired interaction with and phosphorylation of Akt, resulting in compromised signaling and accelerated neurodegeneration (Ohta et al., 2011; Panagiotakopoulou et al., 2020). However, WGE feeding restored downstream Akt signaling by suppressing G2019S mutant protein hyperactivation. Rab10, one of the best-characterized substrates for Lrrk2, mediates several of Lrrk2's cellular functions (Karayel et al., 2020). In *Drosophila*, Rab10 and Lrrk2-G2019S synergistically affect the activity of dopaminergic

neurons, mediating deficits in movement (Fellgett et al., 2021; Petridi et al., 2020). We have shown that WGE treatment downregulated levels of Lrrk2 accumulation and phosphorylated Rab10 (Figure 3F to H), thus alleviating their synergistic toxicity. Several kinase inhibitors have been developed to block the kinase activity of Lrrk2, including of both wild-type Lrrk2 and the G2019S mutant, which could affect endogenous Lrrk2 activity (Sheng et al., 2012). Instead, WGE treatment modulates the phosphorylation status and protein level of the G2019S mutant but not those of wild-type Lrrk2. The new hydrogen bond created at the Ser²⁰¹⁹ autophosphorylation site may provide a docking site for some chemicals in WGE, representing a possible explanatory mechanism that warrants further study (Lang et al., 2015).

The antioxidation and detoxification factor Nrf2 is a target of Akt activation. Nrf2 phosphorylation and HO-1 expression levels revealed that Nrf2 is inactivated in G2019S flies, but it was activated by WGE treatment (Figure 4C and D). Intriguingly, our genetic data indicate that Nrf2 primarily functions in the glia of G2019S flies, with Nrf2 depletion from glia eliminating the beneficial effects of WGE and glial Nrf2 activation partially substituting for WGE feeding (Figure 5B). Cortical neurons express much lower levels of Nrf2 than astrocytes owing to hypo-acetylation and transcriptional repression of the *Nrf2* promoter (Bell et al., 2015). Moreover, neurons express greater amounts of Cullin 3, the scaffold component of the E3 ubiquitin ligase that targets Nrf2 for proteasomal degradation (Jimenez-Blasco et al., 2015). Both those mechanisms render neuronal Nrf2 inert to activation. Nrf2 activation in astrocytes maintains neuronal integrity and function against oxidative insults in response to stress by supplying antioxidants such as glutathione and HO-1 (Kraft et al., 2004; Vargas & Johnson, 2009). Previous study showed that 4-HBA triggers glia to secrete HO-1 via the Nrf2 pathway, protecting neurons from hydrogen peroxide in the primary culture (Luo et al., 2017). In PD models in which wild-type or mutant α -synuclein is overexpressed, activation of neuronal Nrf2 (Barone et al., 2011; Skibinski et al., 2017) or astrocytic Nrf2 (Gan et al., 2012) proved neuroprotective. By genetically manipulating the G2019S fly model, we have shown that WGE-induced Nrf2 activation in glia but not in neurons protects dopaminergic neurons from degeneration and ameliorates impaired locomotion.

432 Astrocyte-like and ensheathing glia are two major types of glia in the *Drosophila* nervous system,
433 surrounding and also extending long processes into neuropils of the brain. These astrocyte-like glia
434 exhibit a morphology and function similar to those of mammalian astrocytes, including reuptake of
435 neurotransmitters and phagocytosis of neuronal debris (Freeman, 2015; Tasdemir-Yilmaz & Freeman,
436 2014). Ensheathing glia of varying morphologies encase axonal tracts and neuropils, regulating neuronal
437 excitability and participating in phagocytosis and injury-induced inflammation (Doherty et al., 2009; Otto
438 et al., 2018). Thus, given their proximity to neurons and similar functions, it is not surprising that both
439 types of glia collectively mediate the protective effects of WGE.

440 Communication between neurons and glia maintains homeostasis, yet also confers the disease state
441 during neurodegeneration. In the *Drosophila* G2019S model, upregulation of the BMP ligand Gbb in
442 dopaminergic neurons activates Mad/Smad signaling in glia, which promotes neuronal degeneration via a
443 feedback mechanism (Maksoud et al., 2019). Surprisingly, although the number of dopaminergic neurons
444 in the fly brain is relatively small, the upregulated pMad signal spreads throughout the brain (Figure 7B),
445 suggesting that BMP can be disseminated over long distances. In PD patients, higher levels of TGF- β 1
446 have been detected in the striatum and ventricular cerebrospinal fluid (Vawter et al., 1996). Thus,
447 members of the TGF- β 1 superfamily such as TGF- β 1 and BMP signaling molecules may represent
448 indicators of neuronal degeneration. Accordingly, disrupting the glia-to-neuron feedback mechanism may
449 sustain neuronal survival. In glia, we found that WGE treatment downregulated the pMad levels that had
450 been increased in the G2019S flies (Figure 7A and B). Nrf2 activation in glia also suppressed the
451 enhanced levels of pMad in G2019S flies (Figure 8B and C). Indeed, our genetic assays indicate that the
452 Nrf2 and Mad pathways interact in the glia of G2019S flies. Thus, WGE exerts its beneficial effects by
453 activating Nrf2 to antagonize the Mad activity that would otherwise contribute to the degeneration of
454 dopaminergic neurons. As a transcriptional activator, Nrf2 induces expression of the inhibitory
455 component Smad7 to form inactive Smad complexes (Song et al., 2019) and the phosphatase subunit
456 PPM1A to alter Smad2/3/4 phosphorylation and DNA binding (Lin et al., 2006). Given that these

components are conserved in *Drosophila*, Nrf2 may employ similar pathways to block Mad signaling in glia.

That glial Nrf2 activation protects neurons is evidenced by our observations of enhanced HO-1 expression (Figure 4C) and increased numbers of dopaminergic neurons (Figure 5E and F). These results support that the role of Nrf2 in glia is to induce expression of antioxidation building blocks, such as phase-II detoxification enzymes, and to enhance inflammatory processes (Hirrlinger & Dringen, 2010; Rojo et al., 2010). In a model of fibrosis, TGF- β /Smad2/3 suppressed expression of the *ARE*-luciferase reporter and glutathione (Ryoo et al., 2014). Moreover, Nrf2 knockdown was shown to reduce expression of the antioxidative enzyme NAD(P)H quinone dehydrogenase 1 (NQO1), thereby elevating cellular oxidative stress and upregulating TGF- β /Smad targeted gene expression (Prestigiacomo & Suter-Dick, 2018). Hence, we propose that WGE promotes Nrf2 activation to antagonize the Smad signaling in glia that is induced by dopaminergic neuron-secreted BMP/Gbb signal during degeneration.

By employing a *LRRK2-G2019S* mouse model, we have also demonstrated that WGE rescues their locomotor coordination, suppresses their centrophobism, and recovers their numbers of dopaminergic neurons and hyperactivated microglia (Figure 9, and Figure 10A to D). Significantly, we found that activity of the TGF- β /Smad2/3 pathway was elevated in nigrostriatal brain lysates, and this activity was also suppressed by WGE treatment (Figure 10E and G). Collectively, these results from fly and mouse PD models indicate that the effectiveness of WGE is likely mediated through conserved Nrf2/Mad pathways (Figure 11). Our findings contribute to our mechanistic understanding of PD and provide potential therapeutic strategies that incorporate the traditional herbal medicine GE.

Materials and Methods

Drosophila stocks and maintenance

All fly stocks were maintained on standard cornmeal-based food medium at 25°C. *Drosophila* stocks sourced from the Bloomington *Drosophila* Stock Center (Indiana University, Bloomington, USA) were: *UAS-mCD8-GFP* (#5137), *elav-GAL4* (#8760), *repo-GAL4* (#7215), *Ddc-LexA* (#54218), *UAS-cncTRiP* (#25984), *Tub-GAL80^{ts}* (#7108), *alrm-GAL4* (#67032), *R56F03-GAL4* (#39157), *UAS-tkv^{Q253D}* (#36536), and *Mad^{K00237}* (#10474). *NP2222-GAL4* (#112830) was from the *Drosophila* Genomics Resource Center and *NP6293-GAL4* (#105188) was from the Kyoto Stock Center. Other stocks include *UAS-Flag-LRRK2-WT* (Lin et al., 2010), *UAS-Flag-LRRK2-G2019S* (Lin et al., 2010), *Ddc-GAL4* (Sang et al., 2007), *ARE-GFP* (Sykietis & Bohmann, 2008), *GstD-GFP* (Sykietis & Bohmann, 2008), *UAS-cncC-FL2* (Sykietis & Bohmann, 2008), *moody-GAL4* (Bainton et al., 2005), and *UAS-Mad* (Takaesu et al., 2006). The two *LexAop* fly lines—*LexAop-LRRK2-WT* and *LexAop-LRRK2-G2019S*—were generated in this study. In brief, the cDNAs for *LRRK2-WT* and *LRRK2-G2019S* were isolated from plasmids (Invitrogen, California, USA) for subcloning into *LexAop* plasmids (Addgene, Massachusetts, USA), which were for microinjection (Fly facility, University of Cambridge, UK). The transgenes were site landed at an attP site on the 2nd chromosome (25C6). For temperature-shift assay of *GAL80^{ts}* flies, parental flies were maintained at 19°C and allowed to mate, before collecting the F1 adults and shifting them to 29°C to inactivate GAL80.

Preparation of WGE and related chemical compounds

Authentication of GE and preparation of WGE were as described previously (Lin et al., 2018; Y. E. Lin et al., 2016). WGE (KO DA Pharmaceutical Co. Ltd., Taoyuan, Taiwan), gastrodin (Wuhan YC Fine Chemical Co., Wuhan, China), and 4-HBA (Sigma-Aldrich, Darmstadt, Germany) were added to freshly-prepared cornmeal-based fly food at indicated final concentrations (w/w). For experiments, one- to three-day-old post-eclosion flies were collected and transferred to fresh food medium twice per week.

Fly locomotion assay

A negative geotaxis climbing assay was performed to assess locomotor activity, and it was conducted according to a previous study with minor modification (Madabattula et al., 2015). Cohorts of 35 flies from each genotype were assayed weekly for six consecutive weeks. Success rates were calculated as the percentage of flies that could climb above the 8-cm mark of a 20-cm cylinder within 10 s.

The free-walking assay protocol was conducted based on a previous report with minor modification (Chen et al., 2014). Cohorts of eight flies were habituated on a 10-cm agar-filled dish for 30 min. The dishes were gently tapped to encourage the flies to walk, which was video-taped for 5 min. Movement tracks were processed in ImageJ and quantified using the Caltech multiple fly tracker (Ctrax).

Immunostaining and immunoblotting of adult fly brains

The protocol for immunostaining whole-mount adult brains was essentially as described previously (Lin et al., 2010; Maksoud et al., 2019). Adult fly brains for each genotype were dissected at the indicated time-points for immunostaining with the following primary antibodies: mouse anti-TH (Immunostar, 22941, 1:1000); mouse anti-repo (Hybridoma Bank DSHB, 8D12, 1:500); chicken anti-GFP (Abcam, ab13970, 1:10000); and rabbit anti-phospho-Smad3 (Ser423/425) (Abcam, ab52903, 1:250) (Smith et al., 2012). Fluorophore-conjugated secondary antibodies were: FITC-conjugated goat anti-mouse IgG (Jackson Lab, AB_2338589, 1:500); Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, A28175, 1:500); Cy3-conjugated goat anti-mouse IgG (Jackson Lab, AB_2338680, 1:500); Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen, A27034, 1:500); and Cy5-conjugated goat anti-rat IgG (Invitrogen, A10525, 1:500). Phalloidin-TRITC (Sigma, P1951, 1:5000) that binds F-actin was also used for counterstaining. Immunofluorescence signals were acquired under confocal microscopy (ZEISS LSM 710, Germany).

Adult brain extracts were prepared according to a previously described protocol (Lin et al., 2010). In brief, ~80 fly heads for each genotype were isolated for extract preparation. Equivalent amounts of

samples (30 µg/20 µL/well) were resolved by SDS-PAGE for immunoblotting. The following primary antibodies were used: rabbit anti-human LRRK2 (Abcam, ab133474, 1:1000); rabbit anti-phospho-LRRK2 (Ser¹²⁹²) (Abcam, ab203181, 1:500); rabbit anti-Akt (Cell Signaling, #4691, 1:1000); rabbit anti-*Drosophila* phospho-Akt Ser⁵⁰⁵ (Cell Signaling, #4054, 1:500); rabbit anti-Nrf2 (Thermo, 710574, 1:1000); rabbit anti-phospho-Nrf2 (Ser⁴⁰) (Thermo Fisher Scientific, PA5-67520, 1:1000); mouse anti-HO-1-1 (Thermo Fisher Scientific, MA1-112, 1:1000); rabbit anti-GAPDH (GeneTex, GTX100118, 1:5000); and rabbit anti-alpha tubulin (Cell Signaling, #2144, 1:10000), followed by blotting with secondary antibodies peroxidase-conjugated goat anti-rabbit IgG (Jackson Lab, AB_2307391, 1:7500) and peroxidase-conjugated goat anti-mouse IgG (Jackson Lab, AB_10015289, 1:7500).

***ARE-GFP* reporter assay**

The antioxidant response element (*ARE*)-*GFP* reporter assay was a modification of the protocol from a previous study (Sykietis & Bohmann, 2008). One-day old virgin female flies (homozygous for *ARE-GFP*) were mated for one day, and then fed with regular food or food containing 0.1% WGE for two more days before imaging for GFP signals. To immunostain the *ARE-GFP* reporter signal in brain, feeding of 0.1% WGE was extended to 5 days. To quantify *ARE-GFP* in adult fly brain, the 0.5-µm confocal images were processed in ImageJ. Mean *ARE-GFP* fluorescence intensities of *mCherry*-labeled glial cells in the PPL1 neuronal cluster were quantified by manually outlining the labeled area to first measure mean GFP signal and then normalizing it to mCherry signal (GFP/mCherry).

Animal care and treatments

Transgenic *LRRK2-G2019S* mice were purchased from Jackson Laboratory (JAX stock #009609, Bar Harbor, ME, USA) and they were maintained at the animal center of the National Taiwan University Hospital (NTUH). Non-transgenic (nTg) and heterozygous transgenic *LRRK2-G2019S* mice were obtained by crossing heterozygous *LRRK2-G2019S* mice with wild-type FVB/NJ mice. Mice at 8.5

months-old were assigned to one of three groups (5 to 6 mice per group): nTg, *LRRK2-G2019S*, and *LRRK2-G2019S* fed with WGE (0.5 g/kg body weight per day) (Lin et al., 2018) for three months.

Behavioral assays

We employed two behavioral tests to assay mouse motor function, i.e., an open field assay to assess spontaneous locomotor activity and CatWalk XT gait analysis to assay coordination. Behavioral experiments were conducted blind to genotype, as described previously (Lin et al., 2020).

Immunohistochemical staining

After three months of WGE treatment, mice were sacrificed at the age of 11.5 months. The substantia nigra and striatum were dissected out. The substantia nigra was subjected to immunostaining, as described previously (Lin et al., 2020). Anti-tyrosine hydroxylase (TH) (Millipore, AB152, 1:200) and anti-ionized calcium-binding adapter molecule 1 (Iba-1) (GeneTex, GTX100042, 1:200) were used as primary antibodies for 24 h at 4°C. Secondary antibodies were DyLight 488 goat anti-rabbit 1:300 and DyLight 546 goat anti-rabbit at 1:200 (25°C for 1 h). Mounting medium with DAPI (GeneTex, GTX30920) was used as a counterstain.

Immunoblotting

Frozen nigrostriatal brain tissues were homogenized and mixed with lysis buffer to determine protein content and for immunoblotting, as described previously (Lin et al., 2020). The membrane was incubated overnight at 4°C with the following primary antibodies: anti-LRRK2 (Abcam, ab133474, 1:5000); anti-phospho-LRRK2 (Ser¹²⁹², Abcam, ab203181, 1:1000); anti-Smad2 (Cell Signaling, 5339T, 1:1000); anti-phospho-Smad2 (Ser465/467, Cell Signaling, 3108T, 1:1000); anti-Smad3 (Cell Signaling, 9523T, 1:1000); anti-phospho-Smad3 (Ser423/425, Abcam, ab52903, 1:1000); and anti-beta actin (Sigma-Aldrich, A5441, 1:5000). After washing, peroxidase-conjugated goat anti-rabbit IgG (GeneTex,

GTX213110-01, 1:5000) or peroxidase-conjugated goat anti-mouse IgG (GeneTex, GTX213111-01, 1:5000) were used as secondary antibodies.

Statistical Analysis

All statistical analyses were carried out in GraphPad PRISM 6 (La Jolla, CA, USA). Data are presented as mean $\pm$ standard error (SEM). Statistical analysis was performed using either student *t*-test or one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. *P* values less than 0.05 ($p < 0.05$) were considered indicative of significance. For exact *n* numbers, *p* values, *F* values, *t*-values, and degrees of freedom of each statistical test, please see the statistical information in the Additional file-Supporting file 2.

Acknowledgements

We thank D. Bohmann (URMC), U. Heberlein (HHMI), S. J. Newfeld (ASU), T.-K. Sang (NTHU), Bloomington Stock Center, *Drosophila* Genomics Resource Center, Kyoto Stock Center and Taiwan Fly Core for providing fly stocks. We thank KO DA Pharmaceutical Co. Ltd. (Taoyuan, Taiwan) and Wuhan YC Fine Chemical Co. (Wuhan, China) for providing WGE and gastrodin, respectively.

Additional information

Ethics approval

All animal procedures were approved by the local ethics committee and the Institutional Animal Care and Use Committee (IACUC) of the National Taiwan University (IACUC approval no. 20180103).

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by grants from the Taiwan Ministry of Science and Technology (MOST-108-2311-B-001-039-MY3) to C.-T. C. S.P. and C.J.H.E. were supported by Parkinson's Disease Society of the United Kingdom (Parkinson's UK), grant H1201.

Authors' contributions

Y.-E.L., C.-H.L., L.-Y.S., and C.-T.C. designed the research. Y.-E.L., E.-P.H., and Y.-C.K. performed the experiments. S.P. and C.J.H.E. contributed new reagents. Y.-E.L., C.-H.L., E.-P.H., and Y.-C.K.

616 analyzed the data. Y.-E.L., C.-H.L., L.-Y.S. and C.-T.C. drafted and revised the manuscript. All authors
617 have read and approved the final manuscript.

618

Additional files

Supporting file 1

Figure supplements.pdf

Figure 1-figure supplement 1. Climbing activity assay of *Ddc>mCD8-GFP* and *Ddc>Lrrk2* flies.

Figure 2-figure supplement 1. WGE treatment prevents dopaminergic neuron loss in *Ddc>G2019S* flies.

Figure 3-figure supplement 1. WGE specifically modulates Lrrk2 accumulation and hyperactivation in

elav>G2019S but not *elav>Lrrk2* flies.

Figure 5-figure supplement 1. WGE rescues the locomotion defect displayed by *Ddc-LexA>G2019S*

flies.

Figure 6-figure supplement 1. Lrrk2 and pLrrk2 levels are maintained upon glial Nrf2 overexpression.

Figure 7-figure supplement 1. *Mad* heterozygosity rescues the impaired locomotion of *Ddc>G2019S*

flies.

Supporting file 2

Source data 1-Statistical Information.xlsx

The file includes all data and the statistical analyses in this article and its supplementary information.

Supporting file 3

Source data 2-Data-WB.pdf

The file includes the uncropped images of the western blotting in this article.

References

- Angeles, D. C., Gan, B. H., Onstead, L., Zhao, Y., Lim, K. L., Dachsel, J., Melrose, H., Farrer, M.,
Wszolek, Z. K., Dickson, D. W., & Tan, E. K. (2011). Mutations in LRRK2 increase
phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. *Hum
Mutat*, 32(12), 1390-1397. <https://doi.org/10.1002/humu.21582>
- Bainton, R. J., Tsai, L. T., Schwabe, T., DeSalvo, M., Gaul, U., & Heberlein, U. (2005). *moody* encodes
two GPCRs that regulate cocaine behaviors and blood-brain barrier permeability in *Drosophila*.
Cell, 123(1), 145-156. <https://doi.org/10.1016/j.cell.2005.07.029>
- Barone, M. C., Sykietis, G. P., & Bohmann, D. (2011). Genetic activation of Nrf2 signaling is sufficient
to ameliorate neurodegenerative phenotypes in a *Drosophila* model of Parkinson's disease. *Dis
Model Mech*, 4(5), 701-707. <https://doi.org/10.1242/dmm.007575>
- Bell, K. F., Al-Mubarak, B., Martel, M. A., McKay, S., Wheelan, N., Hasel, P., Markus, N. M., Baxter, P.,
Deighton, R. F., Serio, A., Bilican, B., Chowdhry, S., Meakin, P. J., Ashford, M. L., Wyllie, D. J.,
Scannevin, R. H., Chandran, S., Hayes, J. D., & Hardingham, G. E. (2015). Neuronal
development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression
of Nrf2. *Nat Commun*, 6, 7066. <https://doi.org/10.1038/ncomms8066>
- Chatterjee, N., & Bohmann, D. (2012). A versatile PhiC31 based reporter system for measuring AP-1 and
Nrf2 signaling in *Drosophila* and in tissue culture. *PLoS One*, 7(4), e34063.
<https://doi.org/10.1371/journal.pone.0034063>
- Chen, A. Y., Wilburn, P., Hao, X., & Tully, T. (2014). Walking deficits and centrophobism in an alpha-
synuclein fly model of Parkinson's disease. *Genes Brain Behav*, 13(8), 812-820.
<https://doi.org/10.1111/gbb.12172>
- Chen, C. Y., Weng, Y. H., Chien, K. Y., Lin, K. J., Yeh, T. H., Cheng, Y. P., Lu, C. S., & Wang, H. L.
(2012). (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN
dopaminergic neurons in a transgenic mouse model of PD. *Cell Death Differ*, 19(10), 1623-1633.
<https://doi.org/10.1038/cdd.2012.42>
- Chen, L., & Feany, M. B. (2005). Alpha-synuclein phosphorylation controls neurotoxicity and inclusion
formation in a *Drosophila* model of Parkinson disease. *Nat Neurosci*, 8(5), 657-663.
<https://doi.org/10.1038/nn1443>
- Chen, P. J., & Sheen, L. Y. (2011). *Gastrodiae Rhizoma* (tian ma): a review of biological activity and
antidepressant mechanisms. *J Tradit Complement Med*, 1(1), 31-40.
<https://www.ncbi.nlm.nih.gov/pubmed/24716103>
- Chen, W. C., Lai, Y. S., Lin, S. H., Lu, K. H., Lin, Y. E., Panyod, S., Ho, C. T., & Sheen, L. Y. (2016).
Anti-depressant effects of *Gastrodia elata* Blume and its compounds gastrodin and 4-

hydroxybenzyl alcohol, via the monoaminergic system and neuronal cytoskeletal remodeling. *J Ethnopharmacol*, 182, 190-199. <https://doi.org/10.1016/j.jep.2016.02.001>

Chou, J. S., Chen, C. Y., Chen, Y. L., Weng, Y. H., Yeh, T. H., Lu, C. S., Chang, Y. M., & Wang, H. L. (2014). (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. *Neurobiol Dis*, 68, 190-199. <https://doi.org/10.1016/j.nbd.2014.04.021>

Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006). *Drosophila pink1* is required for mitochondrial function and interacts genetically with *parkin*. *Nature*, 441(7097), 1162-1166. <https://doi.org/10.1038/nature04779>

Doherty, J., Logan, M. A., Tasdemir, O. E., & Freeman, M. R. (2009). Ensheathing glia function as phagocytes in the adult *Drosophila* brain. *J Neurosci*, 29(15), 4768-4781. <https://doi.org/10.1523/JNEUROSCI.5951-08.2009>

Fellgett, A., Middleton, C. A., Munns, J., Ugbo, C., Jaciuch, D., Wilson, L., Chawla, S., & Elliott, C. J. H. (2021). Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons. *J Parkinsons Dis*. <https://doi.org/10.3233/JPD-202421>

Freeman, M. R. (2015). *Drosophila* central nervous system glia. *Cold Spring Harb Perspect Biol*, 7(11). <https://doi.org/10.1101/cshperspect.a020552>

Gan, L., Vargas, M. R., Johnson, D. A., & Johnson, J. A. (2012). Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. *J Neurosci*, 32(49), 17775-17787. <https://doi.org/10.1523/JNEUROSCI.3049-12.2012>

Grotewiel, M. S., Martin, I., Bhandari, P., & Cook-Wiens, E. (2005). Functional senescence in *Drosophila melanogaster*. *Ageing Res Rev*, 4(3), 372-397. <https://doi.org/10.1016/j.arr.2005.04.001>

Henry, A. G., Aghamohammadzadeh, S., Samaroo, H., Chen, Y., Mou, K., Needle, E., & Hirst, W. D. (2015). Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. *Hum Mol Genet*, 24(21), 6013-6028. <https://doi.org/10.1093/hmg/ddv314>

Hirrlinger, J., & Dringen, R. (2010). The cytosolic redox state of astrocytes: Maintenance, regulation and functional implications for metabolite trafficking. *Brain Res Rev*, 63(1-2), 177-188. <https://doi.org/10.1016/j.brainresrev.2009.10.003>

Houlden, H., & Singleton, A. B. (2012). The genetics and neuropathology of Parkinson's disease. *Acta Neuropathol*, 124(3), 325-338. <https://doi.org/10.1007/s00401-012-1013-5>

- Jang, J. H., Son, Y., Kang, S. S., Bae, C. S., Kim, J. C., Kim, S. H., Shin, T., & Moon, C. (2015). Neuropharmacological potential of *Gastrodia elata* Blume and its components. *Evid Based Complement Alternat Med*, 2015, 309261. <https://doi.org/10.1155/2015/309261>
- Jiang, G., Hu, Y., Liu, L., Cai, J., Peng, C., & Li, Q. (2014). Gastrodin protects against MPP(+)-induced oxidative stress by up regulates heme oxygenase-1 expression through p38 MAPK/Nrf2 pathway in human dopaminergic cells. *Neurochem Int*, 75, 79-88. <https://doi.org/10.1016/j.neuint.2014.06.003>
- Jimenez-Blasco, D., Santofimia-Castano, P., Gonzalez, A., Almeida, A., & Bolanos, J. P. (2015). Astrocyte NMDA receptors' activity sustains neuronal survival through a Cdk5-Nrf2 pathway. *Cell Death Differ*, 22(11), 1877-1889. <https://doi.org/10.1038/cdd.2015.49>
- Jo, K., Jeon, S., Ahn, C. W., Han, S. H., & Suh, H. J. (2017). Changes in *Drosophila melanogaster* sleep-wake behavior due to lotus (*Nelumbo nucifera*) seed and Hwang Jeong (*Polygonatum sibiricum*) extracts. *Prev Nutr Food Sci*, 22(4), 293-299. <https://doi.org/10.3746/pnf.2017.22.4.293>
- Jucaite, A., Svenningsson, P., Rinne, J. O., Cselenyi, Z., Varnas, K., Johnstrom, P., Amini, N., Kirjavainen, A., Helin, S., Minkwitz, M., Kugler, A. R., Posener, J. A., Budd, S., Halldin, C., Varrone, A., & Farde, L. (2015). Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. *Brain*, 138(Pt 9), 2687-2700. <https://doi.org/10.1093/brain/awv184>
- Kam, T. I., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020). Microglia and astrocyte dysfunction in Parkinson's disease. *Neurobiol Dis*, 144, 105028. <https://doi.org/10.1016/j.nbd.2020.105028>
- Karayel, O., Tonelli, F., Virreira Winter, S., Geyer, P. E., Fan, Y., Sammler, E. M., Alessi, D. R., Steger, M., & Mann, M. (2020). Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 Activity in Parkinson's disease. *Mol Cell Proteomics*, 19(9), 1546-1560. <https://doi.org/10.1074/mcp.RA120.002055>
- Kim, T. H., Cho, K. H., Jung, W. S., & Lee, M. S. (2012). Herbal medicines for Parkinson's disease: a systematic review of randomized controlled trials. *PLoS One*, 7(5), e35695. <https://doi.org/10.1371/journal.pone.0035695>
- Kong, E. C., Woo, K., Li, H., Lebestky, T., Mayer, N., Sniffen, M. R., Heberlein, U., Bainton, R. J., Hirsh, J., & Wolf, F. W. (2010). A pair of dopamine neurons target the D1-like dopamine receptor DopR in the central complex to promote ethanol-stimulated locomotion in *Drosophila*. *PLoS One*, 5(4), e9954. <https://doi.org/10.1371/journal.pone.0009954>
- Kraft, A. D., Johnson, D. A., & Johnson, J. A. (2004). Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. *J Neurosci*, 24(5), 1101-1112. <https://doi.org/10.1523/JNEUROSCI.3817-03.2004>

- Kulisevsky, J., Pagonabarraga, J., Pascual-Sedano, B., Garcia-Sanchez, C., Gironell, A., & Trapecio Group, S. (2008). Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. *Mov Disord*, 23(13), 1889-1896. <https://doi.org/10.1002/mds.22246>
- Kumar, H., Kim, I. S., More, S. V., Kim, B. W., Bahk, Y. Y., & Choi, D. K. (2013). Gastrodin protects apoptotic dopaminergic neurons in a toxin-induced Parkinson's disease model. *Evid Based Complement Alternat Med*, 2013, 514095. <https://doi.org/10.1155/2013/514095>
- Lang, C. A., Ray, S. S., Liu, M., Singh, A. K., & Cuny, G. D. (2015). Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. *Bioorg Med Chem Lett*, 25(13), 2713-2719. <https://doi.org/10.1016/j.bmcl.2015.04.027>
- Li, X., Zhang, Y., Wang, Y., Xu, J., Xin, P., Meng, Y., Wang, Q., & Kuang, H. (2017). The mechanisms of Traditional Chinese Medicine underlying the prevention and treatment of Parkinson's disease. *Front Pharmacol*, 8, 634. <https://doi.org/10.3389/fphar.2017.00634>
- Lin, C. H., Lin, H. I., Chen, M. L., Lai, T. T., Cao, L. P., Farrer, M. J., Wu, R. M., & Chien, C. T. (2016). Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity. *Hum Mol Genet*, 25(10), 1965-1978. <https://doi.org/10.1093/hmg/ddw068>
- Lin, C. H., Tsai, P. I., Lin, H. Y., Hattori, N., Funayama, M., Jeon, B., Sato, K., Abe, K., Mukai, Y., Takahashi, Y., Li, Y., Nishioka, K., Yoshino, H., Daida, K., Chen, M. L., Cheng, J., Huang, C. Y., Tzeng, S. R., Wu, Y. S., Lai, H. J., Tsai, H. H., Yen, R. F., Lee, N. C., Lo, W. C., Hung, Y. C., Chan, C. C., Ke, Y. C., Chao, C. C., Hsieh, S. T., Farrer, M., & Wu, R. M. (2020). Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy. *Brain*, 143(11), 3352-3373. <https://doi.org/10.1093/brain/awaa279>
- Lin, C. H., Tsai, P. I., Wu, R. M., & Chien, C. T. (2010). LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. *J Neurosci*, 30(39), 13138-13149. <https://doi.org/10.1523/JNEUROSCI.1737-10.2010>
- Lin, L. C., Chen, Y. F., Lee, W. C., Wu, Y. T., & Tsai, T. H. (2008). Pharmacokinetics of gastrodin and its metabolite p-hydroxybenzyl alcohol in rat blood, brain and bile by microdialysis coupled to LC-MS/MS. *J Pharm Biomed Anal*, 48(3), 909-917. <https://doi.org/10.1016/j.jpba.2008.07.013>
- Lin, L. C., Chen, Y. F., Tsai, T. R., & Tsai, T. H. (2007). Analysis of brain distribution and biliary excretion of a nutrient supplement, gastrodin, in rat. *Anal Chim Acta*, 590(2), 173-179. <https://doi.org/10.1016/j.aca.2007.03.035>
- Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., & Collins, F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science*, 260(5111), 1130-1132. <https://doi.org/10.1126/science.8493557>

- Lin, X., Duan, X., Liang, Y. Y., Su, Y., Wrighton, K. H., Long, J., Hu, M., Davis, C. M., Wang, J., Brunicardi, F. C., Shi, Y., Chen, Y. G., Meng, A., & Feng, X. H. (2006). PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. *Cell*, 125(5), 915-928. <https://doi.org/10.1016/j.cell.2006.03.044>
- Lin, Y. E., Chou, S. T., Lin, S. H., Lu, K. H., Panyod, S., Lai, Y. S., Ho, C. T., & Sheen, L. Y. (2018). Antidepressant-like effects of water extract of *Gastrodia elata* Blume on neurotrophic regulation in a chronic social defeat stress model. *J Ethnopharmacol*, 215, 132-139. <https://doi.org/10.1016/j.jep.2017.12.044>
- Lin, Y. E., Lin, S. H., Chen, W. C., Ho, C. T., Lai, Y. S., Panyod, S., & Sheen, L. Y. (2016). Antidepressant-like effects of water extract of *Gastrodia elata* Blume in rats exposed to unpredictable chronic mild stress via modulation of monoamine regulatory pathways. *J Ethnopharmacol*, 187, 57-65. <https://doi.org/10.1016/j.jep.2016.04.032>
- Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., Moran, T., Ross, C. A., Montell, C., & Smith, W. W. (2008). A *Drosophila* model for LRRK2-linked parkinsonism. *Proc Natl Acad Sci U S A*, 105(7), 2693-2698. <https://doi.org/10.1073/pnas.0708452105>
- Luo, L., Kim, S. W., Lee, H. K., Kim, I. D., Lee, H., & Lee, J. K. (2017). Anti-oxidative effects of 4-hydroxybenzyl alcohol in astrocytes confer protective effects in autocrine and paracrine manners. *PLoS One*, 12(5), e0177322. <https://doi.org/10.1371/journal.pone.0177322>
- Madabattula, S. T., Strautman, J. C., Bysice, A. M., O'Sullivan, J. A., Androschuk, A., Rosenfelt, C., Doucet, K., Rouleau, G., & Bolduc, F. (2015). Quantitative analysis of climbing defects in a *Drosophila* model of neurodegenerative disorders. *J Vis Exp*(100), e52741. <https://doi.org/10.3791/52741>
- Maksoud, E., Liao, E. H., & Haghighi, A. P. (2019). A neuron-glia trans-signaling cascade mediates LRRK2-induced neurodegeneration. *Cell Rep*, 26(7), 1774-1786 e1774. <https://doi.org/10.1016/j.celrep.2019.01.077>
- Mao, Z., & Davis, R. L. (2009). Eight different types of dopaminergic neurons innervate the *Drosophila* mushroom body neuropil: anatomical and physiological heterogeneity. *Front Neural Circuits*, 3, 5. <https://doi.org/10.3389/neuro.04.005.2009>
- Martin, I., Kim, J. W., Dawson, V. L., & Dawson, T. M. (2014). LRRK2 pathobiology in Parkinson's disease. *J Neurochem*, 131(5), 554-565. <https://doi.org/10.1111/jnc.12949>
- Miklossy, J., Arai, T., Guo, J. P., Klegeris, A., Yu, S., McGeer, E. G., & McGeer, P. L. (2006). LRRK2 expression in normal and pathologic human brain and in human cell lines. *J Neuropathol Exp Neurol*, 65(10), 953-963. <https://doi.org/10.1097/01.jnen.0000235121.98052.54>

Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012). LRRK2 inhibition attenuates microglial inflammatory responses. *J Neurosci*, 32(5), 1602-1611. <https://doi.org/10.1523/JNEUROSCI.5601-11.2012>

Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schule, B., Dolmetsch, R. E., Langston, W., Palmer, T. D., & Pera, R. R. (2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell*, 8(3), 267-280. <https://doi.org/10.1016/j.stem.2011.01.013>

Ohta, E., Kawakami, F., Kubo, M., & Obata, F. (2011). LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. *FEBS Lett*, 585(14), 2165-2170. <https://doi.org/10.1016/j.febslet.2011.05.044>

Otto, N., Marelja, Z., Schoofs, A., Kranenburg, H., Bittern, J., Yildirim, K., Berh, D., Bethke, M., Thomas, S., Rode, S., Risse, B., Jiang, X., Pankratz, M., Leimkuhler, S., & Klambt, C. (2018). The sulfite oxidase Shopper controls neuronal activity by regulating glutamate homeostasis in *Drosophila* ensheathing glia. *Nat Commun*, 9(1), 3514. <https://doi.org/10.1038/s41467-018-05645-z>

Panagiotakopoulou, V., Ivanyuk, D., De Cicco, S., Haq, W., Arsic, A., Yu, C., Messelodi, D., Oldrati, M., Schondorf, D. C., Perez, M. J., Cassatella, R. P., Jakobi, M., Schneiderhan-Marra, N., Gasser, T., Nikic-Spiegel, I., & Deleidi, M. (2020). Interferon-gamma signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells. *Nat Commun*, 11(1), 5163. <https://doi.org/10.1038/s41467-020-18755-4>

Petridi, S., Middleton, C. A., Ugbo, C., Fellgett, A., Covill, L., & Elliott, C. J. H. (2020). In vivo visual screen for dopaminergic Rab <--> LRRK2-G2019S interactions in *Drosophila* discriminates Rab10 from Rab3. *G3 (Bethesda)*, 10(6), 1903-1914. <https://doi.org/10.1534/g3.120.401289>

Prestigiacomo, V., & Suter-Dick, L. (2018). Nrf2 protects stellate cells from Smad-dependent cell activation. *PLoS One*, 13(7), e0201044. <https://doi.org/10.1371/journal.pone.0201044>

Price, A., Manzoni, C., Cookson, M. R., & Lewis, P. A. (2018). The LRRK2 signalling system. *Cell Tissue Res*, 373(1), 39-50. <https://doi.org/10.1007/s00441-017-2759-9>

Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018). Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. *Mov Disord*, 33(6), 909-919. <https://doi.org/10.1002/mds.27386>

Rojo, A. I., Innamorato, N. G., Martin-Moreno, A. M., De Ceballos, M. L., Yamamoto, M., & Cuadrado, A. (2010). Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. *Glia*, 58(5), 588-598. <https://doi.org/10.1002/glia.20947>

Ryoo, I. G., Ha, H., & Kwak, M. K. (2014). Inhibitory role of the KEAP1-NRF2 pathway in TGFbeta1-stimulated renal epithelial transition to fibroblastic cells: a modulatory effect on SMAD signaling. *PLoS One*, 9(4), e93265. <https://doi.org/10.1371/journal.pone.0093265>

Sang, T. K., Chang, H. Y., Lawless, G. M., Ratnaparkhi, A., Mee, L., Ackerson, L. C., Maidment, N. T., Krantz, D. E., & Jackson, G. R. (2007). A *Drosophila* model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. *J Neurosci*, 27(5), 981-992. <https://doi.org/10.1523/JNEUROSCI.4810-06.2007>

Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., Cai, F., Song, Q., Li, X., Yue, Z., van der Brug, M. P., Burdick, D. J., Gunzner-Toste, J., Chen, H., Liu, X., Estrada, A. A., Sweeney, Z. K., Scearce-Levie, K., Moffat, J. G., Kirkpatrick, D. S., & Zhu, H. (2012). Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. *Sci Transl Med*, 4(164), 164ra161. <https://doi.org/10.1126/scitranslmed.3004485>

Skibinski, G., Hwang, V., Ando, D. M., Daub, A., Lee, A. K., Ravisankar, A., Modan, S., Finucane, M. M., Shaby, B. A., & Finkbeiner, S. (2017). Nrf2 mitigates LRRK2- and alpha-synuclein-induced neurodegeneration by modulating proteostasis. *Proc Natl Acad Sci U S A*, 114(5), 1165-1170. <https://doi.org/10.1073/pnas.1522872114>

Smith, R. B., Machamer, J. B., Kim, N. C., Hays, T. S., & Marques, G. (2012). Relay of retrograde synaptogenic signals through axonal transport of BMP receptors. *J Cell Sci*, 125(Pt 16), 3752-3764. <https://doi.org/10.1242/jcs.094292>

Sofroniew, M. V., & Vinters, H. V. (2010). Astrocytes: biology and pathology. *Acta Neuropathol*, 119(1), 7-35. <https://doi.org/10.1007/s00401-009-0619-8>

Song, L., He, Y., Ou, J., Zhao, Y., Li, R., Cheng, J., Lin, C. H., & Ho, M. S. (2017). Auxilin underlies progressive locomotor deficits and dopaminergic neuron loss in a *Drosophila* model of Parkinson's disease. *Cell Rep*, 18(5), 1132-1143. <https://doi.org/10.1016/j.celrep.2017.01.005>

Song, M. K., Lee, J. H., Ryoo, I. G., Lee, S. H., Ku, S. K., & Kwak, M. K. (2019). Bardoxolone ameliorates TGF-beta1-associated renal fibrosis through Nrf2/Smad7 elevation. *Free Radic Biol Med*, 138, 33-42. <https://doi.org/10.1016/j.freeradbiomed.2019.04.033>

Sun, J., Xu, A. Q., Giraud, J., Poppinga, H., Riemensperger, T., Fiala, A., & Birman, S. (2018). Neural control of startle-induced locomotion by the mushroom bodies and associated neurons in *Drosophila*. *Front Syst Neurosci*, 12, 6. <https://doi.org/10.3389/fnsys.2018.00006>

Sykotis, G. P., & Bohmann, D. (2008). Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in *Drosophila*. *Dev Cell*, 14(1), 76-85. <https://doi.org/10.1016/j.devcel.2007.12.002>

Takaesu, N. T., Hyman-Walsh, C., Ye, Y., Wisotzkey, R. G., Stinchfield, M. J., O'Connor M, B., Wotton, D., & Newfeld, S. J. (2006). dSno facilitates baboon signaling in the *Drosophila* brain by

switching the affinity of Medea away from Mad and toward dSmad2. *Genetics*, 174(3), 1299-1313.

<https://doi.org/10.1534/genetics.106.064956>

Tasdemir-Yilmaz, O. E., & Freeman, M. R. (2014). Astrocytes engage unique molecular programs to engulf pruned neuronal debris from distinct subsets of neurons. *Genes Dev*, 28(1), 20-33.

<https://doi.org/10.1101/gad.229518.113>

Vaccaro, A., Issa, A. R., Seugnet, L., Birman, S., & Klarsfeld, A. (2017). *Drosophila* Clock is required in brain pacemaker neurons to prevent premature locomotor aging independently of its circadian function. *PLoS Genet*, 13(1), e1006507. <https://doi.org/10.1371/journal.pgen.1006507>

Vargas, M. R., & Johnson, J. A. (2009). The Nrf2-ARE cytoprotective pathway in astrocytes. *Expert Rev Mol Med*, 11, e17. <https://doi.org/10.1017/S1462399409001094>

Vawter, M. P., Dillon-Carter, O., Tourtellotte, W. W., Carvey, P., & Freed, W. J. (1996). TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. *Exp Neurol*, 142(2), 313-322. <https://doi.org/10.1006/exnr.1996.0200>

Wu, J., Wu, B., Tang, C., & Zhao, J. (2017). Analytical techniques and pharmacokinetics of *Gastrodia elata* Blume and its constituents. *Molecules*, 22(7). <https://doi.org/10.3390/molecules22071137>

Zhan, H. D., Zhou, H. Y., Sui, Y. P., Du, X. L., Wang, W. H., Dai, L., Sui, F., Huo, H. R., & Jiang, T. L. (2016). The rhizome of *Gastrodia elata* Blume - An ethnopharmacological review. *J Ethnopharmacol*, 189, 361-385. <https://doi.org/10.1016/j.jep.2016.06.057>

Zhang, Y., Li, M., Kang, R. X., Shi, J. G., Liu, G. T., & Zhang, J. J. (2012). NHBA isolated from *Gastrodia elata* exerts sedative and hypnotic effects in sodium pentobarbital-treated mice. *Pharmacol Biochem Behav*, 102(3), 450-457. <https://doi.org/10.1016/j.pbb.2012.06.002>

Fig. 1

Figure 1. WGE treatment rescues the diminished locomotion of $Ddc>G2019S$ flies.

(A to C) Climbing activities of $Ddc>G2019S$ flies fed on food supplemented with 0.1%, 0.5% or 1.0% WGE (A), 0.1 or 1.0 mM gastrodin (B), and 0.1 or 1.0 mM 4-HBA (C). Controls are $Ddc>Lrrk2$ and $Ddc>G2019S$ flies fed regular food. Bar graphs show the percentages of flies (mean $\pm$ SEM, N = 6) that climbed above 8 cm within 10 sec. (D) Five-minute walking tracks pooled from eight flies each of the $Ddc>Lrrk2$, $Ddc>G2019S$, and $Ddc>G2019S + 0.1\% \text{ WGE}$ groups at week 4. Bar graph at right summarizes their walking distances (mean $\pm$ SEM, N = 8). One-way analysis of variance (ANOVA) with Tukey's post-hoc multiple comparison test: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$, ns, not significant.

Fig. 2

A

B

Figure 2. WGE prevents loss of dopaminergic neurons in *Ddc>G2019S* flies.

(A) Representative adult brain images showing TH-positive dopaminergic neurons in the PPL1 cluster of 2-, 4-, and 6-week-old flies of the *Ddc>Lrrk2*, *Ddc>G2019S*, and 0.1% WGE-fed *Ddc>G2019S* groups. Scale bar: 10 μ m. (B) Average numbers (mean $\pm$ SEM, N = 5) of TH-positive dopaminergic neurons in the PPL1, PPM1/2, PPL2, and PPM3 clusters per brain hemisphere. One-way ANOVA with Tukey's post-hoc multiple comparison test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns, not significant.

Fig. 3

Figure 3. WGE modulates Lrrk2 accumulation and hyperactivation in *elav>G2019S* flies.

(A) Representative immunoblots of 3-day-old adult brain lysates showing expression levels of Lrrk2, pLrrk2 (phosphorylated at Ser¹²⁹²), Akt, and pAkt (phosphorylated at Ser⁵⁰⁵) in *elav>Lrrk2* and *elav>G2019S* flies. (B and C) Quantifications (mean ± SEM, N = 3) of Lrrk2 and pLrrk2/Lrrk2 (B), and Akt and pAkt/Akt (C). (D) Representative immunoblots of 2- and 4-week-old adult brain lysates showing Lrrk2 levels in the fly groups *elav>Lrrk2*, *elav>G2019S*, and *elav>G2019S* fed with 0.1% WGE. (E) Quantification of Lrrk2 levels in 2- and 4-week-old adult brains (mean ± SEM, N = 3). (F) Representative immunoblots of 4-week-old adult brain lysates showing expression levels of Lrrk2, pLrrk2, Rab10 and pRab10 (phosphorylated at Thr⁷³). (G and H) Quantification (mean ± SEM, N = 3) of levels of Lrrk2 and pLrrk2/Lrrk2 (G), and of Rab10 and pRab10/Rab10 (H). One-way ANOVA with Tukey's post-hoc multiple comparison test: * *p* < 0.05, ** *p* < 0.01, ns, not significant.

Fig. 4

Figure 4. WGE activates the Akt-Nrf2 pathway in *elav>G2019S* flies.

(A) Representative immunoblots of 2- and 4-week-old adult brain lysates showing levels of Akt and pAkt in brain extracts of *elav>Lrrk2*, *elav>G2019S*, and WGE-fed *elav>G2019S* flies. (B) Quantification (mean $\pm$ SEM, N = 3) of pAkt/Akt levels in 2- and 4-week-old adult brains. (C) Representative immunoblots of 4-week-old adult brain lysates showing levels of Nrf2, pNrf2 (phosphorylated at Ser⁴⁰), GSK3 β , pGSK3 β (phosphorylated at Ser⁹), and HO-1 in *elav>Lrrk2*, *elav>G2019S*, and WGE-fed *elav>G2019S* flies. GAPDH acted as a loading control in (A) and (C). (D) Quantification (mean $\pm$ SEM, N = 3) of relative protein levels to respective Nrf2, GSK3 β , and HO-1. One-way ANOVA with Tukey's post-hoc multiple comparison test (relative to *elav>G2019S*): * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns, not significant.

Fig. 5

Figure 5. Activation of Nrf2 in glia rescues locomotion defects in *Ddc>G2019S* flies.

(A and B) Requirement of Nrf2 in glia but not neurons for WGE-improved *Ddc>G2019S* climbing activity. (A) Climbing success rates of flies in which *Ddc-GAL4* drives co-expression of *Lrrk2-G2019S* and *mCD8-GFP*, *cncC-FL2* or *cnc-RNAi*. As a control line, *Ddc-GAL4* drives co-expression of *Lrrk2* and *mCD8-GFP*. (B) Climbing success rates of flies in which *Ddc-LexA* drives wild-type *Lrrk2* or *Lrrk2-G2019S* expression and *repo-GAL4* drives *cncC-FL2* or *cnc-RNAi* expression (mean $\pm$ SEM, N = 6 for (A) and (B)). WGE was added to food at a concentration of 0.1% (w/w). (C and D) WGE treatment activates glial Nrf2 signals. ARE-GFP (green) and glial Repo (red) in whole-mount adult brains without (C) or with 0.1% WGE treatment (D) for 5 days. Phalloidin (in blue) reveals brain structures. White arrowheads indicate GFP signals. Scale bar: 50 μ m. Dotted boxes are enhanced views and shown as separate channels at right. (E) Adult brain images showing TH-positive dopaminergic neurons in the PPL1 clusters of 6-week-old *Ddc-LexA>Lrrk2* or *Ddc-LexA>G2019S* flies with *repo-GAL4* control or *repo-GAL4*-driven *cncC-FL2* or *cnc-RNAi* expression. Scale bar: 10 μ m. (F) Average numbers (mean $\pm$ SEM, N = 5) of TH-positive dopaminergic neurons in PPL1 clusters per brain hemisphere are shown. One-way ANOVA with Tukey's post-hoc multiple comparison test (relative to *Ddc>G2019S* (A) or *Ddc-LexA>G2019S; repo-GAL4* (B and F)): ** $p < 0.01$, *** $p < 0.001$, ns, not significant.

Fig. 6

961
962
963

Figure 6. Nrf2 in astrocyte-like and ensheathing glia mediates the effect of WGE treatment in *Ddc>G2019S* flies.

(A) Nrf2 knockdown in astrocyte-like and ensheathing glia abolishes the improved locomotion elicited by WGE treatment in *Ddc>G2019S* flies. Composite bar graph shows climbing success rates for 6-week-old *Ddc-LexA>G2019S* flies with *cnc-RNAi* driven by *repo-GAL4* in all glia, *alrm-GAL4* in astrocyte-like glia, *np2222* in cortex glia, *np6293* in perineurial glia, *R56F03* in ensheathing glia, and *moody-GAL4* in subperineurial glia. (B) Composite bar graph shows climbing success rates (mean $\pm$ SEM, N = 6) for 6-week-old *Ddc-LexA>G2019S* flies with overexpression of Nrf2 in astrocyte-like glia (*alrm>cncC-FL2*) or ensheathing glia (*R56F03>cncC-FL2*). One-way ANOVA and Tukey's post-hoc multiple comparison test (relative to *Ddc-LexA>G2019S; GAL4>cnc-RNAi* (A) or *Ddc-LexA>G2019S; GAL4* (B)): * $p < 0.05$, *** $p < 0.001$, ns, not significant. (C and E) Representative images showing expression of *ARE-GFP* in astrocyte-like glia (*alrm>mCherry*) (C) and ensheathing glia (*R56F03>mCherry*) (E), together with TH-positive dopaminergic neurons in the PPL1 clusters of *Ddc-LexA>Lrrk2*, *Ddc-LexA>G2019S*, or WGE (0.1% w/w)-fed *Ddc-LexA>G2019S* flies. Bar: 5 μ m. GFP channels in the dashed boxes are shown as enhanced views in the lower panel, with glial signals labeled by dashed lines. (D and F) Quantifications (mean $\pm$ SEM, n > 25 for each genotype) of GFP intensities in astrocyte-like glia (D) or ensheathing glia (F). GFP intensities in glia have been outlined manually using the mCherry-positive signals. One-way ANOVA and Tukey's post-hoc multiple comparison test (relative to *Ddc-LexA>G2019S; alrm>mCherry* (D) or *Ddc-LexA>G2019S; R56F03>mCherry* (F)): * $p < 0.05$, *** $p < 0.001$, ns, not significant.

Fig. 7

Figure 7. WGE down-regulates G2019S-induced BMP/Mad signaling.

(A) Representative images of glial pMad staining in the adult PPL1 clusters of *Ddc>Lrrk2*, *Ddc>G2019S*, and WGE-fed *Ddc>G2019S* flies. White arrows indicate pMad signals co-localized with Repo, with single channels for pMad signals shown as insets. Bar: 10 μ m. (B) Quantification (mean $\pm$ SEM, n > 60 for each genotype) of pMad signals normalized to Repo levels in glia of the indicated genotypes. One-way ANOVA and Tukey's post-hoc multiple comparison test (relative to *Ddc>G2019S*): *** $p < 0.001$. (C and D) Climbing success rates (mean $\pm$ SEM, N = 10) at weeks 1-4 demonstrating that WGE treatment rescues locomotion deficits induced by glial overexpression of *Mad* (C) or *tkv^{Q253D}* (D) in *Tub-GAL80^{ts}; repo-GAL4* flies. One-way ANOVA and Tukey's post-hoc multiple comparison test (relative to *repo>Mad* or *repo>tkv^{Q253D}*): ** $p < 0.01$, *** $p < 0.001$. (E and G) Representative images of 4-week-old adult brain showing TH staining of the PPL1 clusters of *Tub-GAL80^{ts}; repo-GAL4*, *Tub-GAL80^{ts}; repo>Mad*, and WGE-fed *Tub-GAL80^{ts}; repo>Mad* flies (E), and *Tub-GAL80^{ts}; repo-GAL4*, *Tub-GAL80^{ts}; repo>tkv^{Q253D}*, and WGE-fed *Tub-GAL80^{ts}; repo>tkv^{Q253D}* flies (G). Bars: 12.5 μ m. (F and H) Bar graphs show mean $\pm$ SEM (N = 5) of TH-positive dopaminergic neurons in the PPL1 clusters of 4-week-old flies. One-way ANOVA and Tukey's post-hoc multiple comparison test (relative to *Tub-GAL80^{ts}; repo>Mad* (F) or *Tub-GAL80^{ts}; repo>tkv^{Q253D}* (H)): *** $p < 0.001$.

Fig. 8

Figure 8. Nrf2 antagonizes BMP/Mad signaling in glia.

(A) Heterozygosity of *Mad* suppresses G2019S mutation-induced locomotion impairment in a negative geotaxis assay. Bar graph shows percentages (mean $\pm$ SEM, N = 6) of 6-week-old flies that climbed above 8 cm within 10 sec. One-way ANOVA and Tukey's post-hoc multiple comparison test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns, not significant. (B) Representative images of pMad staining in the adult brains of *Ddc-LexA>Lrrk2* or *Ddc-LexA>G2019S* flies in which *repo-GAL4* drives expression of *cncC-FL2* or *cnc-RNAi*. Impact of WGE treatment is shown in the rightmost panels. Arrows indicate pMad and Repo dual-positive cells. Insets are enlarged images of the dashed boxes, and dashed lines encompass Repo-positive cells. Bar: 20 μ m. (C) Quantification of the ratio of pMad to Repo (mean $\pm$ SEM, N > 40). One-way ANOVA and Tukey's post-hoc multiple comparison test: *** $p < 0.001$, ns, not significant. (D) Images show pan-glial *ARE-GFP* expression (*repo>mCherry*) in *Ddc-LexA>Lrrk2*, *Ddc-LexA>G2019S*, and *Ddc-LexA>G2019S, Mad^{+/-}* fly brains. GFP channels within the dashed boxes are shown as enhanced views in the inset, with glial signals outlined by dashed lines. Bar: 20 μ m. (E) Quantification for GFP expression levels (mean $\pm$ SEM, n > 13). One-way ANOVA and Tukey's post-hoc multiple comparison test: * $p < 0.05$, *** $p < 0.001$.

Fig. 9

1021
1022

Figure 9. WGE treatment rescues impaired locomotion of *LRRK2-G2019S* mice.

(A) Video-tracked paths for nTg, *LRRK2-G2019S* and WGE-fed *LRRK2-G2019S* mice (8.5 and 11.5 months old) during the open-field test. (B) Quantification of total distance (meters, m), average velocity (centimeters per sec, cm/s), and percentage moving time for 8.5, 9.5, 10.5 and 11.5 months old mice. (C) Captured and converted images of single stance for each paw of 11.5-month-old nTg, *LRRK2-G2019S* and WGE-fed *LRRK2-G2019S* mice in a catwalk analysis. (D) Quantification of stride length for each paw of 8.5- and 11.5-month-old mice. Data in (B and D) are presented as mean $\pm$ SEM (nTg; N = 5, *G2019S*; N = 6, WGE-fed *G2019S*; N = 6). One-way ANOVA and Tukey's post-hoc multiple comparison test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns, not significant. RF – right front; RH – right hind; LF – left front; LH – left hind.

Fig. 10

Figure 10. WGE prevents dopaminergic neuron loss, microglial activation, and phosphorylation of LRRK2, Smad2, and Smad3.

(A and C) Representative images showing TH-positive dopaminergic neurons (A) or Iba-1-positive microglia (C) in the substantia nigra of 11.5-month-old nTg, *LRRK2-G2019S* and WGE-fed *LRRK2-G2019S* mice. Bars: 100 μ m in (A) and 50 μ m in (C). (B and D) Quantification of numbers of TH-positive (B) or Iba-1-positive cells (D) relative to DAPI cells. (E) Representative immunoblots of nigrostriatal lysates prepared from 11.5-month-old nTg, *LRRK2-G2019S* and WGE-fed *LRRK2-G2019S* mice reveal expression levels of LRRK2, pLRRK2 (Ser¹²⁹²), Smad2, pSmad2 (Ser⁴⁶⁵ and Ser⁴⁶⁷), Smad3, and pSmad3 (Ser⁴²³ and Ser⁴²⁵). Actin acted as a loading control. (F and G) Quantifications of LRRK2 and pLRRK2/LRRK2 (F), as well as pSmad2/Smad2 and pSmad3/Smad3 (G). Data in (B, D, F, G) are presented as mean $\pm$ SEM (N = 3). One-way ANOVA and Tukey's post-hoc multiple comparison test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns, not significant.

Fig. 11

Figure 11. The proposed model of WGE in the G2019S-induced neurodegeneration.

Accumulation of the hyperactivated G2019S mutant protein enhances the BMP ligand (Gbb) maturation via up-regulation of Furin 1 translation in dopaminergic neurons. Secreted Gbb binds to the BMP receptor, Tkv, and turns on Mad signaling in glia. The G2019S mutation also decreases the Nrf2 activity in the brain, particularly in glia. Both up-regulated Mad and down-regulated Nrf2 pathways contribute to neurodegeneration. WGE feeding suppresses G2019S hyperactivation in neurons and restores Nrf2 activity mostly in the astrocyte-like and ensheathing glia. WGE-elevated Nrf2 activity in glia antagonizes the BMP/Mad signaling and initiates Nrf2/HO-1 axis in glia, attenuating the stress signals from glia and promoting neuroprotection. Red and green solid arrows ($\rightarrow$) indicate the observed effects exerted by G2019S overexpression and WGE feeding, respectively, in the present study. Red and green dashed arrows ($--\rightarrow$) indicate the proposed actions triggered by Mad signaling and WGE feeding, respectively. Red and green blunt-ended lines ($---|$) indicate the proposed inhibitions by Mad and Nrf2 overexpression, respectively. (P) indicates phosphorylation. The Furin 1-mediated Gbb pathway labeled in gray is modified from previous findings (Maksoud et al., 2019).